In this review, the mechanistic framework for HIF-2α inhibition in ccRCC and with special reference to lipid metabolic process has been discussed, linking with the recent clinical data to show the translational potential and to provide direction for the future development path of treatment targeting HIF-2α (Figure 1). This evidence concerns the gene EPAS1 and nonpapillary renal cell carcinoma.